SUBSCRIBE
SUBSCRIBE
News   Drug Development

BioDelivery Sciences International Anticipates Announcing Phase III BEMA Fentanyl Efficacy Data In April

February 8, 2007 | 
1 min read
MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI) plans to report Phase III data in April, regarding the efficacy of BEMA Fentanyl in the treatment of breakthrough pain in cancer patients.
Clinical research Phase 3
MORE ON THIS TOPIC
Red round circle with a pause button or icon against yellow background.
CAR-T
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
September 1, 2026
 · 
3 min read
 · 
Tristan Manalac
Business decisions. Businessman with question mark confused many roads vector
Cardiovascular disease
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split
August 31, 2026
 · 
3 min read
 · 
Tristan Manalac
Row of Falling Domino Stones Stopped by Red Domino Stone Over Black Background, Risk Management, Intervene or Prevention Concept, 3d Rendering
Cancer
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
August 28, 2026
 · 
2 min read
 · 
Heather McKenzie
Iridescent colors abstract shapes on tar water surface of natural asphalt pit.
cardiovascular disease
‘Worse than expected’ Wainua data muddies water for TTR silencers
August 28, 2026
 · 
2 min read
 · 
Gabrielle Masson